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Adolescent development
Advice in ABC of adolescence is
potentially misleading
Editor—Christie and Viner say that delayed
puberty in boys can be quite distressing but
is almost always a normal variant.1 They say
that boys aged 15 or over with a testicular
volume of 4 ml or more can be reassured
that puberty is beginning and, by inference,
do not require referral to a specialist. This
advice is potentially misleading.
For all that it is a variant of normality,
constitutional delay in growth and puberty
can have adverse psychosocial and skeletal
consequences.2–4 To deny an apubertal teen-
ager the opportunity to choose low dose
androgen treatment until he is into his 16th
year would be unusual by present standards.
Given the likely ensuing timescale, his
doctor might as well refer him straight to an
endocrinologist instead of a paediatrician.
A testicular volume of 4 ml is well within
the range found in boys with irreversible
hypogonadotrophic hypogonadism and
therefore by no means necessarily indicates
that puberty is beginning. Many boys with
hypogonadotrophic hypogonadism start
puberty but fail to progress beyond the early
stages.5 Moreover, a history of cryp-
torchidism (especially if bilateral) or anos-
mia should prompt an even earlier referral.4
Neither does a family history of pubertal
delay necessarily support a diagnosis of
constitutional delay in growth and puberty,
given the high prevalence of constitutional
delay in growth and puberty among first
degree relatives of patients with hypogona-
dotrophic hypogonadism.
A recurring theme in the personal
stories posted on the www.Kallmanns.org
website by men with irreversible hypogona-
dotrophic hypogonadism is of just how diffi-
cult it was for them as teenagers to screw up
the courage to go to see their family doctor
about a lack of secondary sexual characteris-
tics. On being told “not to worry, because it’s
only pubertal delay,” many felt (or were
made to feel) so crushed and foolish that
they then put off seeing a doctor until many
years later.
Richard Quinton consultant endocrinologist
Royal Victoria Infirmary, Newcastle on Tyne
NE3 2NJ
richard.quinton@nuth.nhs.uk
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Author’s reply
Editor—Quinton acknowledges that appar-
ent pubertal delay is a normal variant in
most boys seen by general practitioners or
by paediatric endocrinologists. However, he
says that our advice, that boys aged 15 or
over with a testicular volume of 4 ml or more
can be reassured that puberty is beginning,
is potentially misleading, as 4 ml testes are
within the range found in adult men with
the uncommon condition of irreversible
hypogonadotrophic hypogonadism.
Our advice is appropriate for boys who
present to general practitioners. The
absence of any signs of puberty, or lack of
further progression through puberty over
the next six months should, of course, be
viewed with suspicion and merit referral to a
paediatric endocrinology service for full
investigation, including consideration of
conditions such as hypogonadotrophic
hypogonadism.
Quinton thinks that even the normal
variant of constitutional delay in growth and
puberty can have adverse psychosocial con-
sequences.1 However, newer larger studies
have shown that boys who are small or
whose adolescence is delayed are not
psychologically disadvantaged.2 Rather than
overtreating numbers of normal boys, we
focus on improving the communication
skills of general practitioners in discussing
issues such as pubertal timing with young
people.
Russell Viner consultant in adolescent medicine and
endocrinology
University College London Hospitals NHS
Foundation Trust and Great Ormond Street
Hospital NHS Trust, London W1T 3AA
rviner@ich.ucl.ac.uk
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Cognitive behaviour therapy
for adolescents with chronic
fatigue syndrome
Data are insufficient and conclusion
inappropriate
Editor—I have concerns about the design
and interpretation of the study reported by
Stulemeijer et al on cognitive behaviour
therapy for adolescents with chronic fatigue
syndrome.1 The trial arms were not matched
for the number of contacts with healthcare
professionals. Experience from larger and
more carefully controlled randomised inter-
ventional trials of patients with chronic
fatigue syndrome has clearly shown that
short term improvement in symptoms is
related directly to the maintenance of regular
contacts with healthcare professionals rather
than the therapeutic effect of the intervention
itself and consequently, the improvement is
not sustained once the contact is lost.2
The authors did not offer patients in
their waiting list the opportunity to meet
therapists regularly for five months but with-
out having cognitive behaviour therapy. Few
follow up data on patients in the interven-
tion arm show that the specific treatment
benefit was carried forward without regular
contacts with the therapists. A cautious
approach is essential in inferring direct ben-
efit from cognitive behaviour therapy in the
intervention arm (as opposed to short term
benefit from close contact with therapists).
The level of activity in some of their partici-
pants whom the authors considered to be
passive remained unclear.
In their summary points the authors
claim that cognitive behaviour therapy was
effective by challenging patients’ belief that
activity aggravated symptoms. Epidemio-
logical data, however, confirm that fatigue
made worse by exercise is a characteristic
feature of adolescents at risk of chronic
fatigue syndrome.3 Encouraging activity in
disabled patients is entirely different from
challenging an accepted feature of the
disease. A rhetorical approach towards a
physically and emotionally challenging con-
dition does not help recovery and only
encourages therapeutic failure.
Abhijit Chaudhuri senior lecturer in clinical
neurosciences
University of Glasgow, Institute of Neurological
Sciences, Glasgow G51 4TF
ac54p@udcf.gla.ac.uk
Competing interests: None declared.
1 Stulemeijer M, de Jong LWAM, Fiselier TJW, Hoogveld
SWB, Bleijenberg G. Cognitive behaviour therapy for ado-
lescents with chronic fatigue syndrome: randomised
controlled trial. BMJ 2005;330:14-8. (1 January.)
Letters
789BMJ VOLUME 330 2 APRIL 2005 bmj.com
2 Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Wood-
ward C, Howe I, et al. Effect of galantamine hydrobromide
in chronic fatigue syndrome: a randomized controlled
trial. JAMA 2004;292:1195-204.
3 Mears CJ, Taylor RR, Jordan KM, Binas HG. Sociodemo-
graphic and symptom correlates of fatigue in an adolescent
primary care sample. J Adolesc Health 2004;35:528e.21-6.
Authors’ reply
Editor—Chaudhuri’s concerns relate to a
possible placebo effect and the way we treat
our patients. We consider it unlikely that the
positive effects of our treatment are attribut-
able mainly to non-specific treatment factors,
since the results were maintained at eight
month follow up even in the absence of con-
tacts with the therapist (unpublished data).
Moreover, others have shown that cognitive
behaviour therapy was more effective than
attention control conditions shortly after
treatment and at long term follow-up.1–3
At the start of therapy all patients experi-
enced severe limitations in performing activi-
ties appropriate to age. A characteristic belief
of patients with chronic fatigue syndrome,
especially in case of passive patients, is that
fatigue is made worse by exercise. This cogni-
tion, although functional in the first phase of
the condition, is dysfunctional in the longer
term and maintains activity avoidance and
symptoms. By challenging these and other
activity related cognitions, activity regulation
is possible. Thus, patients are taught to
regulate and increase their physical and other
activities in a systematic and safe way. Our
results show that this is possible. The
distinction between physically passive and
relatively active patients, based on actometry,
is helpful to select the correct approach to
help the patient.
As in other chronic conditions, we do not
have one treatment that leads to recovery in
all patients. We believe that our study clearly
shows that many of the participants benefited
from cognitive behaviour therapy and were
able to function as normal adolescents again.
Maja Stulemeijer junior researcher
Lieke W A M de Jong child psychologist
Theo J W Fiselier paediatrician
Sigrid W B Hoogveld junior researcher
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How to prevent caesarean
deliveries deserves more study
Editor—Declercq et al bring to light “no
indicated risk” as a new classification of cae-
sarean delivery.1 Like other classes of caesar-
ean delivery, annual rates of caesarean
sections with no indicated risk have been
increasing in the United States and around
the world. In the context of these increases,
we are surprised that methods of care that
might prevent caesarean delivery have not
been pursued more aggressively.
Caesarean delivery is strongly correlated
to the age of the mother, parity, and increas-
ing gestational age within the term period of
pregnancy.1 2 If caesarean delivery is an
adverse outcome worthy of prevention, if risk
factors for caesarean delivery can be identi-
fied, and if a latent period exists between the
identification of risk and the development of
situations requiring caesarean delivery then
perhaps a preventive approach—encourag-
ing patients with risk factors to enter labour
before their risk can become disease—could
lower caesarean delivery rates safely.
Our working group recently described
the use of risk driven, prostaglandin assisted
induction of labour, and this intervention
was associated with a rate of caesarean deliv-
ery of only 4%.3 While Declercq et al think
that research should be done to elucidate
whether the risks of primary caesarean
delivery in cases of no indicated risk will be
offset by associated benefits, we hope that an
equal amount of time and effort will be
spent on developing and testing methods
that might safely prevent, or lower, rates of
caesarean delivery performed for this and
the other more traditional indications.
James M Nicholson assistant professor
james.nicholson@uphs.upenn.edu
Lisa C Kellar first year fellow
Peter F Cronholm clinical instructor
Department of Family Practice and Community
Medicine, 2 Gates, Hospital of the University of
Pennsylvania, 3400 Spruce Street, Philadelphia, PA
19104, USA
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Early epidurals increase
caesarean rate, meta-analysis
shows
Editor—The study reported by Mayor in
her news item uses the term “neuraxial anal-
gesia” and claims that early epidurals do not
increase the rate of caesarean deliveries.1 2
This is confusing as the study was not of
early epidural analgesia, and the oxytocin
augmentation rate of 75% at first analgesia
makes for lack of generalisability.
The claim that women need not worry
that early epidurals will lead to increased cae-
sareans is false.3 This trial was about two
methods of helping women with pain in early
labour. In the so called epidural arm, on their
first request for analgesia, women received
intrathecal fentanyl, and in the narcotic arm,
hydromorphone. On their second request,
almost two thirds of women in both arms
were 4 cm or more dilated. In the intrathecal
“epidural” arm, they received low dose epi-
durals; in the narcotic arm, hydromophone.
This trial, as others that have contributed
to the Cochrane meta-analysis,4 5 showed no
increase in caesareans in the presence of
epidural analgesia, but does not acknowl-
edge that most women were in active labour
at randomisation, when most will do well.
Wong et al,2 like Sharma et al, the major
contributors to the Cochrane meta-analysis,4
have shown only that when women’s pain in
the latent phase is managed with intrathecal,
narcotic, or other pharmacological or
non-pharmacological means, an epidural in
the active phase of labour does not increase
the rate of caesareans.
The role of an early epidural in contrib-
uting to increases in caesarean rates has yet
to be studied in an randomised controlled
trials, but the sensitivity analysis in the
Cochrane meta-analysis, after removing late
randomisation studies, shows that early epi-
durals to more than double caesarean rates.
Michael C Klein physician
BC Women’s Hospital, Vancouver, British
Columbia, Canada V6H 3VJ
mklein@interchange.ubc.ca
Competing interests: None declared.
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Clomipramine and neuroleptic
malignant syndrome
Literature on adverse reactions to
psychotropic drugs continues to confuse
Editor—Haddow et al describe a severe
adverse drug reaction but create an oxy-
moron in describing clomipramine induced
“neuroleptic malignant syndrome.”1
Clomipramine is not a neuroleptic and
therefore by definition cannot cause this
syndrome (any more than it can cause anti-
convulsant hypersensitivity syndrome). The
description is consistent with serotonin tox-
icity, a well described adverse reaction to
serotonergic antidepressants. In attempting
to describe a new adverse drug reaction,
Haddow et al have focused on non-specific
clinical features that are present in many
drug induced neuropsychiatric syndromes.2
Clomipramine, a potent serotonin reuptake
inhibitor, has been associated with hyper-
thermia and was more correctly labelled as
serotonin toxicity.3 4 Muscle rigidity and
raised muscle enzyme activities also occur in
severe serotonin toxicity.4
Neuroleptic malignant syndrome is an
idiosyncratic reaction to therapeutic doses
of neuroleptic agents.5 A pragmatic clinical
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description of the syndrome includes four
primary features: autonomic lability, hyper-
thermia (pyrexia) without other cause,
extrapyramidal syndrome (cog-wheel or
lead pipe rigidity), and encephalopathy.2
Despite superficial clinical similarities
between neuroleptic malignant syndrome
and serotonin syndrome, they are usually
easily differentiated on the basis of careful
neurological examination. Neuroleptic
malignant syndrome is associated with lead
pipe rigidity, bradykinesia, and other
extrapyramidal features.5 Conversely in
serotonin syndrome there is hyperkinesia,
hyperreflexia, and clonus.4 5
Descriptions of adverse reactions to psy-
chotropic drugs need detailed clinical
descriptions of neuromuscular, central, and
autonomic features. Using ambiguous or
non-specific criteria to label adverse reac-
tions as a particular syndrome while
ignoring the pharmacology of the impli-
cated drug may lead to false associations
between particular drugs and clinical syn-
dromes and to inappropriate treatment.
Geoffrey K Isbister clinical toxicologist
Newcastle Mater Misericordiae Hospital, Edith
Street, Waratah, NSW 2298, Australia
gsbite@ferntree.com
Nicholas A Buckley associate professor
Clinical Pharmacology and Toxicology, Canberra
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Authors’ reply
Editor—Clomipramine is not a neuroleptic
and is classed as an “antidepressant.”
However, as mentioned in our article, this
drug has an appreciable blocking effect at
dopamine receptor sites, the traditional
domain of the neuroleptic drug. This is a
weak effect, but it is more potent than several
other antidepressant agents.1 This action is
recognised in the current edition of the
BNF, which says that neuroleptic malignant
syndrome may, very rarely, arise in the
course of antidepressant treatment.2
We also made reference to 50 worldwide
reports received regarding clomipramine
and neuroleptic malignant syndrome or
suspected neuroleptic malignant syndrome,
in addition to four reports received by the
Committee on Safety of Medicines and two
published case reports.
We agree that we should have made
clear that this patient’s muscle rigidity was of
the lead pipe variety, although some widely
accepted diagnostic criteria require only
severe muscle rigidity.3 The diagnostic crite-
ria that we tabulated were based on
Levinson and Sternabach and referenced in
our article.4 5
We described in this patient an earlier
diagnosed episode of serotonin syndrome,
and no clinical evidence of rigidity was
found on that occasion.
In view of the action at dopamine sites of
clomipramine, and the statement in the BNF
from the BMA and the Royal Pharmaceutical
Society of Great Britain,we would continue to
support our diagnosis of neuroleptic malig-
nant syndrome in this informative case.
Alison Haddow consultant in old age psychiatry
Royal Cornhill Hospital, Aberdeen AB25 2ZH
alison.haddow@gpct.Grampian.scot.nhs.uk
Martin Wilson clinical lecturer
Department of Medicine for the Elderly, University
of Aberdeen, Aberdeen AB25 2ZD
Competing interests: None declared.
1 Tatsumi M, Groshan K, Blakely R, Richelso E. Pharmaco-
logical profile of antidepressant and related compounds at
human monoamine transporters. Europ J Pharm 1997;
340:249-58
2 Diagnostic and statistical manual for mental disorders, fourth
edition (DSM-IV). Washington DC: American Psychiatric
Press, 1994:739-42.
3 British Medical Association, Royal Pharmaceutical Society
of Great Britain. British national formulary 2004;48:
4.3.1;196.
4 Levenson JL. Neuroleptic malignant syndrome. Am J
Psychiatry 1985;142:1137-45
5 Sternabach H. The serotonin syndrome. Am J Psychiatry
1991;148:705-13.
Risks of gene therapy should
be weighed against lack of
alternatives for many diseases
Editor—Kimmelman provided a compre-
hensive discussion about the risks and ethics
of gene therapy.1 We certainly cannot predict
the future, but the risks should be weighed
against the complete lack of alternative
options for many of the diseases discussed.
The two cases of T cell leukaemia in the X
linked severe combined immunodeficiency
gene therapy trial are presented as typical
examples of malignant transformation. How-
ever, that treatment entailed the modification
of immature stem cells, which may present
additional risks.2 Much work is being done in
vector design to lessen these risks. Relative
risks and toxicities are also likely to be linked
to the disease type and target cell. For
non-lethal disorders such as the inherited
retinal dystrophies, minimising risk is of even
more importance. However, gene transfer to
a post-mitotic cell such as a photoreceptor by
using a vector with limited genomic integra-
tion, such as recombinant adeno-associated
virus, is much less likely to be mutagenic.
The risks of gene therapy must be
weighed carefully against the risks and
efficacy of existing treatment. Conventional
treatments such as organ transplantation,
which are no longer considered experimen-
tal, are associated with substantial morbidity
and mortality.3 The difficult balance is to
steer a path between the ethical application
of new untested strategies with the potential
to improve health care, and a position of
caution. As with conventional medicines, the
risks and ethics of gene therapy should
probably be reflected in this light.
Robert E MacLaren MRC research fellow
Robin R Ali professor of human molecular genetics
Division of Molecular Therapy, Institute of
Ophthalmology, University College London,
London EC1V 9EL
Adrian J Thrasher professor of paediatric
immunology
Molecular Immunology Unit, Institute of Child
Health, UCL, London WC1N 1EH
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Need for expertise based
randomised controlled trials
Expertise based design has shortfalls
Editor—Devereaux et al discussed the need
for expertise based randomised controlled
trials for surgical procedures.1
Firstly, the use of expertise based designs
does not necessarily enhance the validity of
a surgical trial. Surgical outcome does not
depend solely on the operation; other
factors that influence the results of an
operation are heterogeneous and immeas-
urable (postoperative management, the sur-
gical team, equipment). A different bias is
introduced by the expertise based design,
the influence of the overall performance of
surgeon A v B, and in this regard, expertise
based design is not necessarily a more valid
comparison of operation A v B.
Secondly, the use of expertise based
designs does not necessarily enhance the
applicability of a surgical trial. The expertise
based design assumes that an operation will
only be performed by a select few. This is
rarely the case, and hence the results will not
reflect the true performance of an operation
introduced to the general public (performed
by a variety of surgeons).
Moreover, the results of expertise based
design trials do not take into account any
learning curve that exists when a new
operation is introduced. The initial rates of
adverse outcomes are higher when a
surgeon refines an existing operative tech-
nique,2 never mind a new one.
A solution is to perform a randomised
trial that has a balanced surgical expertise in
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both arms in proportions reflective of the
population that will perform the operations.
Academics can analyse the “expertise”
subgroup, while the rest of us can look at the
overall results to determine how an opera-
tion will really perform.
Eric Lim specialist registrar
Papworth Hospital, Papworth Everard, Cambridge
CB3 8RE
eric.lim@cvsnet.org
Competing interests: None declared.
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Surgical research shares many
similarities with psychotherapy research
Editor—Of course the expertise based ran-
domised trial, mooted for surgical proce-
dures by Devereaux et al,1 is the norm in
psychotherapy research when comparing
two different psychotherapies. A similar
debate on the interpretation of such trials
occurred in the psychotherapy literature.2
Research in surgery and psychotherapy
share other similarities beyond having to
account for practitioner expertise. There is
the issue of blindness—hard to achieve for
both patient and doctor in these
disciplines—as well as the “why test it, it’s obvi-
ous it makes a difference” argument. Both
disciplines could learn from each other about
the design and analysis of clinical research.
Simon Hatcher senior lecturer in psychiatry
Department of Psychological Medicine, Faculty of
Medical and Health Sciences, University of
Auckland, Private Bag 92019, Auckland 1, New
Zealand
s.hatcher@auckland.ac.nz
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Target SHOs and registrars for
communication skills training
Editor—Kidd et al argue that undergradu-
ates need to learn clinical and communica-
tion skills side by side.1 Every doctor needs
communication skills, from pathologists to
surgeons and physicians. In the Netherlands
undergraduates spend considerable time on
how to communicate with patients. But I
think that this is targeting the wrong group,
and time is taken away from essential
preclinical and clinical studies. Students
learn to talk to simulated patients with, for
example, a Dukes’s D colon cancer, at a time
in their studies when they don’t know what
cancer is, what a Dukes’s D colon cancer
means, and what the impact is on a patient.
Students receive this kind of training in their
second year and have forgotten about it
when they become senior house officers.
Senior house officers (SHOs) and regis-
trars should be doing the training.We do the
damage in our “bad news” talks. We know
what we are talking about, and we do it daily.
We should be the ones filmed on camera
and evaluated. This should be done with cli-
nicians with experience, together with “com-
municators,” and not only by people who
studied communication skills who have
never had to tell anybody that they have
cancer and are dying, or let a family know
that a patient has died. The impact of this is
greater than most people can imagine, and I
think poor communication on those sub-
jects often reflects the inability of the doctor
to deal with his or her own feelings.
The same goes for communicating with
colleagues. In my hospital, emergency
departments are now filmed in major
trauma cases, and the people on the floor
are actually the ones being filmed. Evalua-
tion is then done by the surgeons, together
with a psychologist.
Communication skills are essential, but
not at the expense of medical students’ pre-
clinical and clinical curriculum. The target
groups should therefore be senior house
officers and specialist registrars.
Erik T Walbeehm specialist registrar plastic surgery
Rotterdam, 3022 BC, Netherlands
erikwalbeehm@mac.com
Competing interests: None declared.
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Old docs and new tricks
Seasoned doctors may be better than
young doctors at some things
Editor—Spurgeon reports that the doctors’
standards of care drop with years in
practice.1 When I began clinical practice in
the late 1980s I thought that one key to
being a “good doc” was keeping up with the
latest drugs and technologies. I was dis-
mayed to see seasoned colleagues who were
slow to change.
I then saw many new drugs get pulled
from the market (rofecoxib is not the first
non-steroidal anti-inflammatory drug to be
withdrawn) and various medical fads come
and go. Evidence based medicine appropri-
ately shed light on the poor evidence
available to support most things that physi-
cians do.
Armed with this keener analytical
approach, I came to realise that most claims
of benefit are greatly exaggerated compared
with absolute incremental changes and that
most patients are not like trial subjects.
Although an intervention might benefit a
population, it is much less certain that it will
benefit the patient who sits before me.
I suspect that seasoned doctors are
better than their junior colleagues at some
things, and worse at others.Maybe the ability
to see the big picture, diagnostically and
therapeutically, is enhanced by experience.
Meanwhile the emphasis on the newest
treatment detail might wane. Perhaps that is
a reason why I have conflicting opinions
about whether doctors get better with time.
Louis B Jacques physician
918 Barracuda Cove Court, Annapolis, MD 21401,
USA
JacquesL@georgetown.edu
Competing interests: None declared.
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Efficiency is important
Editor—In British general practice, where
everyday demand exceeds capacity, the
efficient general practitioner is king. That is
one thing that experience should bring. If all
general practitioners followed every guide-
line the system would collapse, and although
a few patients would have exemplary care,
many would have no care at all as they would
just not get seen because they would find the
wait intolerable. Perhaps this is what happens
now in secondary care, where care delivered
is often very good but access is less and less.
Accepted practice is often developed for
a “one issue patient.” Reality means multi-
issue patients, who themselves have limited
ability to follow all the investigation and
“treatment” recommended by the single
issue academic establishment. Many indica-
tions for treatment are immediately met
with contraindications. Experience allows
general practitioners to cut back on too
much excess investigation and treatment
while still striving to meet the guidelines.
Protecting the patient from the iatro-
genic harm of excess health care used to be
a core skill of the general practitioner. Is this
being taken away from us as well?
A system that fails to value the soft end
points and often efficient and effective care
that experience brings will have to restruc-
ture to meet the demand and that inevitably
will lead to a hugely expanded system with
resource implications. I am not disputing the
findings of the paper reported by Spurgeon,
that the standard of care may drop with
years spent in practice,1 but the immediate
common sense illogically of its hypothesis
and conclusions make me advise to proceed
down this route with caution. Being a doctor
is already a difficult job. Being advised that
all your thoughtful patient experience has
actually made you a worse doctor is demoti-
vating. Perhaps experienced doctors and
patients would have a different set of criteria
about what good care is?
Graeme M Mackenzie general practitioner
Whitehaven CA28 7RG
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